Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30341827 | 1.00 | OPRM1 (0.43) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| SCHEMBL29425244 | 1.00 | OPRM1 (0.43) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| Hydrochloric Acid SCHEMBL11594041 | 0.99 | OPRM1 (0.43) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| Hydrochloric Acid SCHEMBL11591298 | 0.99 | OPRM1 (0.43) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| Hydrochloric Acid SCHEMBL11581218 | 0.99 | OPRM1 (0.43) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| Acetic Acid SCHEMBL1307421 | 0.97 | OPRM1 (0.44) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| Acetic Acid SCHEMBL2268904 | 0.97 | OPRM1 (0.44) | OPRM1OPRK1NMUR2NMUR1CXCR4 | |
| Acetic Acid SCHEMBL20769309 | 0.95 | OPRM1 (0.47) | OPRM1OPRK1NMUR2NMUR1NTSR2 | |
| Acetic Acid SCHEMBL20769302 | 0.95 | OPRM1 (0.47) | OPRM1OPRK1NMUR2NMUR1NTSR2 | |
| Acetic Acid SCHEMBL2193528 | 0.95 | OPRM1 (0.47) | OPRM1OPRK1NMUR2NMUR1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRM1 3352/4885OPRK1 3229/4885NMUR2 4295/4885 |
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | OPRM1 4215/4885OPRK1 4410/4885NMUR2 1020/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRM1 2317/4885OPRK1 2737/4885NMUR2 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.